COVID-19 studies:  C19 studies: C19:  IvermectinIVM Vitamin DV.D HC QHC Q Vitamin CV.C ZincZn PVP-IPVP-I REGNREGN LY-CoVLY RemdesivirRMD

9/21 Early treatment study
Lofgren et al., Open Forum Infectious Diseases, doi:10.1093/ofid/ofaa500 (preprint 9/21) (Peer Reviewed) (not included in the study count)
Safety of Hydroxychloroquine among Outpatient Clinical Trial Participants for COVID-19
Source   PDF   Share   Tweet
Analysis of 2,795 outpatients not showing significant safety concerns with HCQ. No deaths were related to HCQ. There was one serious event requiring hospitalization, identical to the frequency with placebo.

Lofgren et al., 9/21/2020, peer-reviewed, 26 authors.
Details of all 230 studies    Meta analysis
Please submit corrections, updates, or comments.
Submit